Novo Nordisk Weight Loss Pill

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

Reuters · 1d

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.

Kiplinger on MSN · 12d

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Novo Nordisk shares surge

CNBC on MSN · 1d

Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth quarter came in at 28.

Business Insider · 20h

NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales

invezz on MSN · 22h

Novo Nordisk shares surge as Wegovy sales drive profit beat

Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected fourth-quarter net profit, driven by soaring demand for its obesity treatment,

Weight loss pill could replace injections, would be transformative for millions

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

11hon MSN

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

3don MSN

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

15hon MSN

Why Novo Nordisk (NVO) Is Climbing Today

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for ...

12d

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

10d

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Yahoo Finance12d

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk's stock (NVO) rose more than 8% in Friday ... The highest dose, 20 mg, provided the highest weight loss.

16h

Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results